Specific adverse events: serious thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy probably leads to higher specific adverse events: serious thromboembolic events compared with chemotherapy (moderate certainty).
1 finding from 1 review
Adverse events: hypertension · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy probably leads to higher specific adverse events: hypertension compared with chemotherapy (moderate certainty).
1 finding from 1 review
Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy probably leads to higher serious adverse events compared with chemotherapy (moderate certainty).
1 finding from 1 review
Economic evaluation · women with persistent, recurrent, or metastatic cervical cancer
1 finding from 1 review
Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (advanced stages)
Dose‐intensified chemotherapy showed no clear difference in secondary malignant neoplasms compared with ABVD‐like chemotherapy (with or without radiotherapy (low certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (advanced stages)
Dose‐intensified chemotherapy showed no clear difference in death compared with ABVD‐like chemotherapy (with or without radiotherapy (moderate certainty).
1 finding from 1 review
Progression/relapse · Patients with untreated Hodgkin lymphoma (advanced stages)
Dose‐intensified chemotherapy probably leads to lower progression/relapse compared with ABVD‐like chemotherapy (with or without radiotherapy (moderate certainty).
1 finding from 1 review
Participants requiring dose reduction · early triple‐negative breast cancer
Platinum‐containing chemotherapy probably leads to higher participants requiring dose reduction compared with chemotherapy without platinum (moderate certainty).
1 finding from 1 review
Anaemia (grade ≥ 3) · early triple‐negative breast cancer
Platinum‐containing chemotherapy probably leads to higher anaemia (grade III/IV) compared with chemotherapy without platinum (moderate certainty).
1 finding from 1 review
Febrile neutropenia (grade III/IV) · early triple‐negative breast cancer
Platinum‐containing chemotherapy showed no clear difference in febrile neutropenia (grade III/IV) compared with chemotherapy without platinum (moderate certainty).
1 finding from 1 review
Grade III or IV renal toxicity · early triple‐negative breast cancer
1 finding from 1 review
Quality of life · early triple‐negative breast cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality (calculated instead of overall survival) · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
ATRA in addition to chemotherapy showed no clear difference in mortality (instead of overall survival) compared with chemotherapy only (moderate certainty).
1 finding from 1 review
Quality of life · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality, relapse and progresses (instead of disease‐ or relapse‐free survival) · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
ATRA in addition to chemotherapy showed no clear difference in mortality, relapse and progresses (instead of disease‐ or… compared with chemotherapy only (moderate certainty).
1 finding from 1 review
On‐study mortality · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
ATRA in addition to chemotherapy showed no clear difference in on‐study mortality compared with chemotherapy only (moderate certainty).
1 finding from 1 review
Severe adverse effects (grade 3+): Infection · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
ATRA in addition to chemotherapy showed no clear difference in infection grade III/IV compared with chemotherapy only (moderate certainty).
1 finding from 1 review
Grade 3 to 4 diarrhoea · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
It is very uncertain whether ATRA in addition to chemotherapy changes diarrhoea grade III/IV compared with chemotherapy only (very low certainty).
1 finding from 1 review
Toxicity: grade 3 or 4 nausea ± vomiting · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
It is very uncertain whether ATRA in addition to chemotherapy changes nausea/vomiting grade III/IV compared with chemotherapy only (very low certainty).
1 finding from 1 review
Cardiac toxicity grade III/IV · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
It is very uncertain whether ATRA in addition to chemotherapy changes cardiac toxicity grade III/IV compared with chemotherapy only (very low certainty).
1 finding from 1 review